Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.5
Journals
Pharmaceutics
Announcements
share announcement

Announcements

19 September 2025
MDPI Webinar | The Science Behind the Prize: 2025 Nobel Physiology or Medicine Roundtable, 6 October 2025


Coinciding with the announcement of the 2025 Nobel Prize in physiology or medicine, this forum underscores the importance of recognizing outstanding achievements that push the boundaries of human knowledge and understanding. It represents a valuable opportunity to exchange ideas on the advancements driving scientific progress and to inspire the next generation of gifted scientists.

General topics of discussion for this event will include the following:

  • Breakthrough research shaping the future of physiology or medicine;
  • Reflecting on past Nobel Prize-winning work and its legacy;
  • The key trends driving innovation in physiology or medicine today;
  • Exploring the societal and scientific contributions of physiology or medicine research.

Date: 6 October 2025
Time: 3:30 p.m. CEST | 9:30 a.m. EDT | 9:30 p.m. CST (Asia)
Webinar ID: 852 3554 5031

Register now for free! 

After registering, you will receive a confirmation email with information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.

Unable to attend? Please register anyway; the session will be recorded, and we will let you know when the recording is available for viewing.

Program:

Speaker

Agenda

Time in CEST

Time in EDT

Time in CST Asia

MDPI Host

Opening Remarks

3:30–3:35 p.m.

9:30–9:35 a.m.

9:30–9:35 p.m.

Speakers:
Prof. Dr. Jacek Z. Kubiak
Prof. Dr. Carlos Moreno
Prof. Dr. Claus Jacob

Expert Commentary: Breakthroughs and Future Impacts of Physiology or Medicine Research

3:35–4:15 p.m.

9:35–10:15 a.m.

9:35–10:15 p.m.

 

Break

4:15–4:20 p.m.

10:15–10:20 a.m.

10:15–10:20 p.m.

MDPI Host

Stating the Prize Winner

4:20–4:25 p.m.

10:20–10:25 a.m.

10:20–10:25 p.m.

Speakers:
Prof. Dr. Jacek Z. Kubiak
Prof. Dr. Carlos Moreno
Prof. Dr. Claus Jacob

Reflective Discussion: What the Nobel Prize Means for Science and Society

4:25–4:45 p.m.

10:25–10:45 a.m.

10:25–10:45 p.m.

MDPI Host

Closing Remarks

4:45–4:50 p.m.

10:45–10:50 a.m.

10:45–10:50 p.m.


Webinar Keynote Speakers:

  • Prof. Dr. Jacek Z. Kubiak, CNRS/University Rennes UMR 6290, Institute of Genetics and Development of Rennes (IGDR), Rennes, France;
  • Prof. Dr Carlos S. Moreno, Department of Pathology & Laboratory Medicine, Department of Biomedical Informatics, Department of Urology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA;
  • Prof. Dr Claus Jacob, Division of Bioorganic Chemistry, School of Pharmacy, University of Saarland, Saarland, Germany.

For more information about this webinar, please visit the following link: https://sciforum.net/event/NPR2025PM.

If you have any questions about this webinar, please contact webinar@mdpi.com.

MDPI Webinar Secretariat

15 September 2025
Interview with Dr. Po-Han Chao—Winner of the Pharmaceutics Best PhD Thesis Award


We are pleased to share with you a recent interview conducted with Dr. Po-Han Chao, the winner of the Pharmaceutics 2024 Best PhD Thesis Award.

The following is an interview with Dr. Po-Han Chao:

1. Could you introduce your research work during your PhD studies and the main objectives of your doctoral dissertation?
My PhD centered on nanomedicine for cancer immunotherapy. Specifically, I worked on using liposomes to deliver resiquimod, a TLR7/8 agonist, into the tumor microenvironment. My dissertation, entitled “Resiquimod-Loaded Cationic Liposomes Cure Mice with Peritoneal Carcinomatosis and Induce Specific Anti-Tumor Immunity”, showed that this approach not only eradicated tumors in mice via cationic liposomes but also triggered long-lasting, tumor-specific immune memory. The bigger goal was to bring drug delivery and immunotherapy together, finding ways to make the immune system itself fight back against aggressive cancers.

2. Did you encounter any difficulties in carrying out this research? If yes, how did you overcome them and what strategies did you use to stay focused and motivated?
Yes, definitely. Technically, optimizing the liposomes to produce stable formulations with good drug loading took many rounds of trial and error. On top of that, the COVID-19 lockdowns made things harder because lab access was restricted for long stretches of time. That slowed down experiments and added a lot of uncertainty about timelines. What helped me was breaking the work into smaller milestones and focusing on what I could do outside the lab, like analyzing data or planning the next set of experiments. Talking with my supervisor and lab mates kept me grounded, and celebrating small wins along the way helped me stay motivated. Ultimately, I reminded myself of the bigger picture—that this research could contribute to new treatment options for patients who really need them.

3. In your opinion, what key qualities should an excellent PhD graduate possess? Do you have some advice for doctoral students who have not yet graduated?
I would say resilience, curiosity, and clear communication. Resilience because experiments will fail more often than they succeed, curiosity because that is what keeps you digging deeper, and communication because good science needs to be shared in a way that others can understand and use. For students still on their journey, do not measure your progress only by papers or data points. The PhD is about developing how you think, troubleshoot, and collaborate. Those skills stay with you much longer than a single publication.

4. What are your future research plans and what are your long-term career goals?
I want to keep working at the intersection of nanomedicine and cancer immunotherapy, with a focus on translating preclinical findings into clinically viable treatments. Long term, my goal is to bridge academia and industry to help move innovative therapies from the lab into clinical trials, where they can make a real difference for patients with advanced cancers.

5. As an author, what factors do you consider most important when choosing a journal for publication? Pharmaceutics is an open access journal—what are your thoughts on the open access publishing model?
When I choose a journal, I look for the right audience, a fair and constructive review process, and good visibility. The whole point is to make sure the research reaches the people who can use it and build on it. For open access, I think it is really valuable. It removes barriers and makes science accessible not only to researchers but also clinicians and even patients. Fees can be challenging, but overall, I see open access as the right direction for science as it makes knowledge more inclusive and accelerates collaboration.

12 September 2025
Meet Us at the 2025 Chinese Biomaterials Congress (CSBM 2025), 9–12 October 2025, Shaoxing, China


Conference: 2025 Chinese Biomaterials Congress (CSBM 2025)
Date: 9–12 October 2025
Location: Shaoxing, China

MDPI will be attending the 2025 Chinese Biomaterials Congress as an exhibitor. We welcome researchers from different backgrounds to visit and share their latest ideas with us.

The Chinese Biomaterials Congress is the most comprehensive, largest, and highest-level comprehensive academic exchange platform in its field. The 2025 Chinese Biomaterials Congress ence and Exhibition of New Technologies, Products, and Instruments (CSBM 2025), hosted by the Chinese Society for Biomaterials and organized by the Zhejiang University Shaoxing Research Institute, will be held at the Zhejiang Shaoxing International Convention and Exhibition Center from 9 to 12 October 2025. Driven by the new quality productivity policy, biomaterials, as a key area of strategic emerging industries, are experiencing unprecedented development opportunities.

The conference will focus on cutting-edge biomaterials science, technological innovation, application of research findings, and regulatory science, sharing the latest research findings and practical experiences and discussing the future direction of the biomaterials field. Experts, scholars, researchers, physicians, and entrepreneurs from renowned research institutions, medical institutions, businesses, and regulatory agencies, engaged in the research, development, production, testing, regulation, and clinical practice of biomaterials and medical devices, will attend.

Here is a list of just a few of the cutting-edge topics for all:
1. Innovative bone regeneration biomaterials and bone health;
2. Cardiovascular and peripheral vascular materials and devices;
3. Advanced manufacturing cutting-edge technologies;
4. Tissue and organ regenerative medicine materials;
5. Biomedical metal materials;
6. Nanobiomaterials and pharmaceutical development;

The following MDPI journals will be represented:

If you are planning to attend this conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit the following website: https://2025.csbm.org.cn/.

3 September 2025
Join Us at the MDPI at the University of Toronto Career Fair, 23 September 2025, Toronto, ON, Canada


Date: 23 September 2025
Time: 11:00 a.m.–4:30 p.m
Location: The Chelsea Hotel, 33 Gerrard Street West, Toronto

MDPI is thrilled to announce our participation in the University of Toronto’s largest career fair, taking place at the St. George Downtown Campus. This exciting event brings together thousands of students, graduates, and professionals looking to connect with top employers and explore career opportunities.

We invite all attendees to visit the MDPI booth to discover how you can be part of one of the world’s leading open access academic publishers. Whether you are passionate about scientific research, editorial work, marketing, or supporting global innovation in publishing, we want to meet YOU!

What to expect at our booth:

  • Learn more about MDPI’s mission and global impact;
  • Explore exciting career opportunities in publishing, editorial, communications, and more;
  • Network with our team and ask questions about working at MDPI.

Whether you’re just starting your career or looking to take the next step, don’t miss this opportunity to connect with MDPI. Bring your resume, your curiosity, and your questions—we look forward to seeing you there!

For additional information on the Career Fair and Open MDPI positions, please visit the following links:

1 September 2025
MDPI INSIGHTS: The CEO’s Letter #26 – CUJS, Head of Ethics, Open Peer Review, AIS 2025, Reviewer Recognition

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Society of China University Journals (CUJS) visit to MDPI Basel

In August, we had the pleasure of welcoming a delegation from the Society of China University Journals (CUJS) to our Basel headquarters. The visit was part of CUJS’s broader European tour, which included meetings with several major publishing organizations.

Purpose of the visit

The delegation’s stop in Basel involved an introductory meeting and knowledge-sharing with a view to identifying potential collaboration opportunities with MDPI. The CUJS team shared an overview of the Chinese scientific publishing landscape, including recent policy developments, and gave us insights into the journals and services they operate across China’s academic institutions.

MDPI presentations

We used the opportunity to introduce CUJS to MDPI’s mission, structure, and recent achievements. I presented on the latest developments at MDPI and our role in supporting global open access, addressing many follow-up questions from the delegation. Warm thanks are due to the following colleagues for their contributions to the session:

  • Liliane Auwerter (Conference Organizer, Scientific Officer and Sustainability Specialist) shared an overview of our editorial process, including the quality indicators we use to track peer-review performance.
  • Renato Merki (Publication Ethics Assistant) presented on behalf of our Research Integrity and Ethics team, emphasizing our commitment to responsible publishing.
  • Silvano Bonfatti (Product Manager) introduced the JAMS platform, highlighting how it supports efficient journal management for editors and publishers alike.
  • Aimar Xiong (Publisher, Section Managing Editor) and Giuliano Braccini (Office Manager) facilitated the meeting, offering clarity in response to specific questions, building the relationship during and beyond the meeting itself.

“Building relationships with organizations such as CUJS allows us to increase our visibility and reputation”

Why is this important?

China is one of the world’s largest producers of scientific research, with its universities and research institutes playing a key role in global scholarly publishing. Building strong relationships with influential organizations such as CUJS allows us to increase our visibility and reputation vis-à-vis the Chinese academic community, share best practices, learn from differing publishing models, and explore collaborations that have the potential to enhance the quality, reach, and diversity of our journals.

Looking ahead

It was a productive and friendly exchange that reflected our shared commitment to advancing scholarly communication and improving journal publishing practices. We value these visits, which allow us to create collaborations with stakeholders in the global academic community.

Our Basel office is a hub for hosting international delegations, partners, and collaborators. We look forward to creating more global connections that support our mission.

Impactful Research

Appointment of Dr. Tim Tait-Jamieson as Head of Publication Ethics

As part of our ongoing commitment to research integrity and publishing excellence, I am delighted to announce that we have appointed Dr. Tim Tait-Jamieson as Head of Publication Ethics.

In this role, Tim will lead the development of our ethics strategy and oversee the continued growth of the Publication Ethics Department, which is based across our offices in Basel, Manchester, Belgrade/Novi Sad, and Cluj. Guided by the principles of effective prevention and efficient resolution, the department plays an essential role in ensuring the highest standards of integrity throughout our editorial processes.

Department focus

Working closely with internal teams and external partners, the Publication Ethics Department focuses on refining our policies, aligning our operations with international best practices, and addressing complex cases with fairness and transparency. This work is critical in supporting our editors, reviewers, and authors, reinforcing MDPI’s contribution to the global dialogue on research integrity.

“Research integrity is something to which we all contribute through our daily work at MDPI”

About Tim

Tim joined MDPI in 2021 and has held several roles within the Publication Ethics Department, most recently serving as Research Integrity Lead. Based in our Basel office, he brings a strong academic background, with a Ph.D. in Geography from the University of Fribourg, Switzerland, and a proven track record of leadership in research integrity.

Research integrity is something to which we all contribute through our daily work at MDPI. I look forward to Tim’s leadership as we continue investing in the people, processes, and partnerships that uphold the trust and credibility of scholarly publishing.

Read more:

Inside MDPI

How and why MDPI offers Open Peer Review

At MDPI, we are committed to advancing openness and transparency in scholarly publishing. One area where we’ve taken a leadership role is peer review. Since 2014, MDPI has offered authors the option of open peer review, giving them the opportunity to publish reviewer comments alongside their papers. Each year, more authors are choosing this path, helping to build trust in the editorial process and provide valuable context for the research we publish.

Jack McKenna (Senior Content Specialist, MDPI) recently wrote an informative piece looking at the impact and importance of open peer review at MDPI. He highlights how this approach not only benefits readers but also gives well-deserved recognition to our reviewers, who generously dedicate their time and expertise to the academic community.

I encourage you to read this blogpost to see how MDPI is helping set standards for transparency in scholarly publishing.

Coming Together for Science

Recap of MDPI’s AIS 2025 Conference in Kuala Lumpur

Entering the month of August, we held The 2nd International Conference on AI Sensors and Transducers (AIS 2025) in Kuala Lumpur, Malaysia.

“AIS is quickly becoming a premier event in the field”

The second edition of AIS brought together 335 attendees from across Asia and beyond, including participants from China, Japan, Korea, and Southeast Asia. The event, chaired by Prof. Dr. Toshihiro Itoh (University of Tokyo), Prof. Dr. Sang-Woo Kim (Yonsei University), and Prof. Dr. Chengkuo Lee (National University of Singapore), continues to grow in reputation and has become an important platform for researchers and students to present their work, exchange ideas, and build international collaborations.

AIS is quickly becoming a premier event in the field, with participants highlighting its quality of service, its expanding academic network, and the value it delivers in the context of tightening research budgets in the region.

It was also excellent to see our new MDPI journal AI Sensors, which originated from a conference topic, host a successful launch party at the event.

Highlights from participant feedback:

  • Southeast University (China) sent a student delegation and considers AIS a regular fixture for Ph.D. students in need of international conference experience.
  • CAS Aerospace Information Research Institute sent a 10-member delegation and plans to further promote AIS internally.
  • Japanese researchers regard AIS as a must-attend event, placing it on a par with IEEE conferences and citing the benefits of networking and exchange.
  • Korean academics praised the organization and noted improved perceptions of MDPI among their institutions, viewing AIS as a strategic opportunity to deepen engagement in the region.

Award winners

We recognized the recipients of the Best Presentation, Best Scientist, Best Poster, and Best Student Paper awards, whose contributions set a standard for academic excellence. The full award announcement is available here.

Looking ahead

The 3rd International Conference on AI Sensors and Transducers will be held from 5 to10 August 2026 in Jeju, Korea. The General Chairs will be Prof. Inkyu Park (Korea Advanced Institute of Science and Technology), Prof. Zhou Li (Tsinghua University), Prof. Xinge Yu (City University of Hong Kong), and Prof. Chengkuo Lee (National University of Singapore). We look forward to bringing together innovators, researchers and experts who are shaping the future at the intersection of sensors, sensing technology, transducers and artificial intelligence.

Thank you

Our conference team managed this event with great agility and professionalism and are already planning improvements to make the conference even more accessible. Special thanks to the National University of Singapore for their support, and to our entire conference team and collaborators for their dedication.

AIS is gaining momentum, and we look forward to supporting its role as a bridge between MDPI and the global academic community.

“Our conference team managed this event with great agility and professionalism”

Closing Thoughts

Recognizing our outstanding reviewers

As we close this edition of the newsletter, I would like to spotlight MDPI’s 2024 Outstanding Reviewer Awards, which showcase a group of winners whose contributions often go unseen but are essential to the integrity of scholarly publishing: our reviewers.

In 2024, more than 215,000 reviewers dedicated their time and expertise to MDPI journals. From this community, we are proud to recognize 356 recipients of the Outstanding Reviewer Awards, who went above and beyond by providing timely, thorough and constructive feedback.

These awards are not only a token of our appreciation but also a reflection of the values we stand for: rigor, fairness and collaboration in advancing science.

To explore the full list of awardees across disciplines, from life sciences to the humanities, please visit the following pages:

About MDPI Awards

To recognize the academic community, MDPI journals regularly offer various awards to researchers in specific fields. Serving as a source of recognition and inspiration, these awards help increase the influence of scholars who have been credited with outstanding achievements and are making a significant contribution to the advancement of their respective fields.

To explore more opening Outstanding Reviewer Awards, please click here.

To all our reviewers: thank you for being the foundation of trust that makes open access publishing possible!

Stefan Tochev
Chief Executive Officer
MDPI AG

18 August 2025
Welcoming New Early Career Editorial Board Members of Pharmaceutics


Pharmaceutics (ISSN: 1999-4923) is pleased to announce the following 74 researchers who have been added to our group of 2025–2026 Early Career Editorial Board Members. Please join us in congratulating them on joining the Pharmaceutics community!

Name: Dr. Tatiane Cogo Machado
Affiliation: Faculty of Science, School of Mathematical and Physical Sciences, University of Technology Sydney (UTS), Ultimo, Australia
Homepage: https://orcid.org/0000-0002-0182-7152
Research interests: solid state pharmaceutics; formulation of poorly soluble drugs; pharmaceutical cocrystals; amorphous formulations; crystal and particle engineering, solubility; dissolution kinetics

Name: Dr. Dalila Miele
Affiliation: Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90033, USA
Homepage: https://orcid.org/0000-0001-6396-7452
Research interests: drug delivery systems; tissue engineering; pharmaceutical nanotechnology; gene therapy; non-viral vectors; translational pharmaceutical technology

Name: Dr. Valentyn Mohylyuk
Affiliation: Leading Research Group, Faculty of Pharmacy, Rīga Stradiņš University, 21 Konsula St., LV-1007 Riga, Latvia
Homepage: https://science.rsu.lv/en/persons/valentyn-mohylyuk
Research interests: pharmaceutical technology (hot-melt extrusion, roll-compaction, tableting, coating, FDM 3D printing, etc.); oral dosage forms formulations with tailored drug release: (incl. solubility/BA enhanced); optimization of the pharmacokinetics and custom properties of dosage forms; and cutting-edge methods of oral dosage form pre-formulation and formulation

Name: Dr. Maria Vivero-Lopez
Affiliation: Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
Homepage: https://www.idfarmausc.es/miembro/maria-vivero-lopez/
Research interests: biomaterials; hydrogels; medicated contact lenses; polymeric micelles; ocular nanoparticles; antibiofilm materials; drug delivery systems; ocular drug delivery; controlled release

Name: Dr. Eduard Preis
Affiliation: Department of Pharmaceutics and Biopharmaceutics, University of Marburg, 35037 Marburg, Germany
Homepage: https://www.uni-marburg.de/de/staff-info?dn=supn7k7fpq
Research interests: nanoparticles; nanofibers; liposomes; electrospun fibers; photodynamic therapy; gene therapy; drug delivery

Name: Dr. Antonella Grigoletto
Affiliation: Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy
Homepage: https://www.dsfarm.unipd.it/antonella-grigoletto-0
Research interests: targeted lipid nanoparticles; nucleic acid delivery; targeted liposomes; drug delivery; peptides and proteins delivery; mAbs; PEG; hyaluronic acid; hydrogels; technological formulation

Name: Dr. Małgorzata Anna Marć
Affiliation: Cell Engineering Laboratory, La Paz University Hospital Health Research Institute (IdiPAZ), 28046 Madrid, Spain
Homepage: https://orcid.org/0000-0002-5183-801X
Research interests: ADMETox; pharmacology; anticancer research; multidrug resistance; efflux pumps; cytotoxicity; apoptosis; antibacterial assays; pharmaceutical biotechnology; drug discovery & development; selenocompounds; small molecules; probiotics

Name: Dr. Amina Tucak-Smajić
Affiliation: Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Sarajevo, Zmaja od Bosne 8, 71000 Sarajevo, Bosnia and Herzegovina
Homepage: https://ffsa.unsa.ba/index.php/fakultet/katedre/katedra-za-farmaceutsku-tehnologiju  
Research interests: lipid nanoparticles; microRNA delivery; targeted drug delivery; pharmaceutical nanotechnology; transdermal drug delivery; microneedles

Name: Dr. Tingting Peng
Affiliation: College of Pharmacy, Jinan University, Guangzhou 511436, China
Homepage: https://yx.jnu.edu.cn/2025/0314/c37237a831737/page.htm
Research interests: transdermal drug delivery; dissolving microneedles; nano-microparticulate drug delivery

Name: Dr. Maryam Oroujeni
Affiliation: Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden
Homepage: https://www.uu.se/en/contact-and-organisation/staff?query=N15-423
Research interests: theranostic; precision oncology; targeted radiotracer

Name: Dr. Sherif Ashraf Fahmy
Affiliation: Department of Pharmaceutics and Biopharmaceutics, University of Marburg, 35037 Marburg, Germany
Homepage: https://www.uni-marburg.de/en/staff-info?dn=qr2loukxgx
Research interests: drug delivery; controlled release; nanomedicine; herbal medicine; chemotherapeutics; cancer therapy; biomedical applications

Name: Dr. Aun Raza
Affiliation: Academy of Pharmacy, Xi’an Jiaotong-Liverpool University, Suzhou, China
Homepage: https://orcid.org/0000-0003-4960-000X
Research interests: drug delivery systems, nanoparticles; hydrogels; lipid-based carriers

Name: Dr. Pengwen Chen
Affiliation: Department of Bioengineering, The University of Tokyo, Tokyo, Japan
Homepage: https://bmc.t.u-tokyo.ac.jp/lab-members/
Research interests: nanomedicine; drug delivery; cancer therapy; immunotherapy

Name: Dr. Antonio José Guillot
Affiliation: Department of Pharmacy and Pharmaceutical Technology, University of Valencia, Valencia, Spain
Homepage: https://producciocientifica.uv.es/investigadores/333786/detalle
Research interests: pharmaceutical technology; drug delivery; controlled drug release; nanotechnology; microneedles; microfluidics; liposomes; biomimetic nanoparticles

Name: Dr. Pankaj Dwivedi
Affiliation: Department of Administrative and Pharmaceutical Sciences, University of Health Science and Pharmacy in St. Louis, St. Louis, MO 63110, USA
Homepage: https://icts.wustl.edu/people/pankaj-dwivedi-phd/
Research interests: drug delivery; nanoparticles; nanomedicine; tissue-specific targeting; tumor targeting

Name: Dr. Giulia Di Prima
Affiliation: Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, 90123 Palermo, Italy
Homepage: https://www.unipa.it/persone/docenti/d/giulia.diprima/en/index.html
Research interests: ex-vivo permeation; nanosystems; drug delivery systems; biopolymers; buccal tablets; microparticles; dissolution kinetics

Name: Dr. Tianqun Lang
Affiliation: Lingang Laboratory, Shanghai, China
Homepage: https://www.lglab.ac.cn/ 
Research interests: nano drug delivery system; biomimetic drug delivery system; lung cancer therapy

Name: Dr. Łukasz Szeleszczuk
Affiliation: Department of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
Homepage: https://chemiafizyczna.wum.edu.pl/node/115
Research interests: polymorphism; DFT calculations on molecular solids; NMR parameter calculations; molecular dynamics simulations; phase transitions

Name: Dr. Gustavo A. Hernandez-Fuentes
Affiliation: Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
Homepage: https://orcid.org/0000-0003-4685-3095
Research interests: natural products; cancer; medicinal chemistry; organic chemistry; metabolic syndrome

Name: Dr. Xiao Lin
Affiliation: School of Life Science, Northwestern Polytechnical University, Xi'an 710072, China
Homepage: https://teacher.nwpu.edu.cn/linxiao.html
Research interests: biomaterials; extracellular vesicles; bone and joint degeneration

Name: Dr. Heyang Zhang
Affiliation: BioTherapeutics Division, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
Homepage: https://www.universiteitleiden.nl/en/staffmembers/heyang-zhang/publications#tab-3
Research interests: drug delivery; nanomedicines; nucleic acids

Name: Dr. Guangsheng Du
Affiliation: West China School of Pharmacy, Sichuan University, Chengdu 610041, China
Homepage: https://pharmacy.scu.edu.cn/info/1059/6149.htm
Research interests: vaccine delivery; cancer vaccination; lymph-node targeting; immune tolerance induction; microneedle delivery system

Name: Dr. Mara Mădălina Mihai
Affiliation: 1. Department of Oncologic Dermatology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania;
2. Elias Emergency University Hospital, Bucharest, Romania
Homepage: https://umfcd.ro/wp-content/uploads/2024/CONC_DID_2024_2025/INFORMATII_CANDIDATI/PER_NEDETERMINATA/FACULTATEA_DE_MEDICINA/%5BLL%5DMihai_Mara-Madalina%28C2%29.pdf
Research interests: bioactive materials; nanotechnology; targeted therapy; biologic therapy; chronic wounds; wound healing; chronic skin infections; microbial biofilms; skin cancer; melanoma

Name: Dr. Carla Serri
Affiliation: Department of Medicine, Surgery and Pharmacy, University of Sassari, Via Muroni 23/a, 07100 Sassari, Italy
Homepage: https://www.uniss.it/it/ugov/person/144901
Research interests: polymeric nanoparticles; nanomedicine; pharmaceutical technology; lipid nanoparticles; nanoprecipitation; nanoparticles loading poorly soluble drugs; drug delivery

Name: Dr. Mengyang Liu
Affiliation: School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1010, New Zealand
Homepage: https://profiles.auckland.ac.nz/m-liu
Research interests: transdermal and dermal delivery; nanoparticulate delivery system; skin barriers; peptide drug delivery

Name: Dr. Djordje Medarevic
Affiliation: Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, 11221 Belgrade, Serbia
Homepage: http://pharmacy.bg.ac.rs/en/about-us/research-associate/6693/dr-sc-%C4%91or%C4%91e-medarevi%C4%87/
Research interests: poorly soluble drugs; solid dispersions; amorphous formulation; nanocrystals; experimental design; 3D printing

Name: Dr. Sandeep Urandur
Affiliation: Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA
Homepage: https://orcid.org/0000-0001-5803-077X
Research interests: drug product development; mechanistic modelling; DOE; personalized medicine; infectious diseases and cancer

Name: Dr. Katona Gábor
Affiliation: Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
Homepage: http://www2.pharm.u-szeged.hu/gytfi/hu/munkatarsak/oktato-kutato/143-dr-katona-gabor
Research interests: nose-to-brain delivery; nanomedicine; albumin nanoparticles; polymeric micelles; freeze-drying

Name: Dr. Dake Hao
Affiliation: Department of Surgery, University of California, Davis, CA, USA
Homepage: https://bmegg.ucdavis.edu/people/dake-hao
Research interests: disease mechanisms and the interplays between cells and the extracellular environment; cutting-edge tissue engineering tools/technologies and next-generation medical products for regenerative medicine and clinical therapies

Name: Dr. Wufa Fan
Affiliation: Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Homepage: https://www.imm.ac.cn/kydw/yjyzzkyg/07c6e375d6974c12ac1ebe072eed26b6.htm
Research interests: synthesis and application of biomedical materials; cell transcytosis-based drug delivery; nanomedicine for tumor immunotherapy; biological effects of nanomedicine

Name: Dr. Cosmin Stefan Butnarasu
Affiliation: Institute of Pharmacy, Biopharmaceuticals, Freie Universität, 14195 Berlin, Germany
Homepage: https://orcid.org/0000-0001-8620-3391
Research interests: mucosal drug delivery; mucin and mucin-inspired materials; nanotechnology; biological barrier permeability and in vitro models

Name: Dr. Silvestre Manuel Bongiovanni Abel
Affiliation: Research Institute for Materials Science and Technology, INTEMA (UNMdP—CONICET), Mar del Plata, Argentina
Homepage: https://www.conicet.gov.ar/new_scp/detalle.php?id=41788&keywords=Bongiovanni+Abel+Silvestre+Manuel&datos_academicos=yes
Research interests: electrospinning; functional polymeric nanomaterials; nanocomposites; hydrogels; biomedical applications of nanomaterials; antimicrobials properties; tissue engineering

Name: Dr. Luis Ibarra
Affiliation: Institute of Environmental Biotechnology and Health (INBIAS), National Council for Scientific and Technical Research (CONICET) and National University of Río Cuarto (UNRC), Rio Cuarto, Argentina
Homepage: https://bicyt.conicet.gov.ar/fichas/p/en/luis-exequiel-ibarra   
Research interests: nanomedicine; cell therapy; tumor microenvironment; photodynamic therapy; cell targeting

Name: Dr. Yang Liu
Affiliation: School of Pharmacy, Zhengzhou University, Zhengzhou, China
Homepage: https://www5.zzu.edu.cn/yxy/info/1114/4115.htm
Research interests: controlled release preparations; targeted preparations; gene delivery systems; molecular pharmaceutics

Name: Dr. Sindhu Subramanian
Affiliation: Amrita Vishwa Vidyapeetham, Coimbatore, India
Homepage: https://www.amrita.edu/faculty/s-sindhu/
Research interests: waste to energy; drug delivery systems; waste water treatment

Name: Dr. Helin Xu
Affiliation: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
Homepage: https://yxy.wmu.edu.cn/info/1125/7968.htm
Research interests: biologics for IBDs treatments; specially designing novel delivery system of biologics; bio-adhesive hydrogel; inflammation-targeted platform or smart-release nano/micro-sized delivery systems

Name: Dr. Narsimha Mamidi
Affiliation: Wisconsin Centre for Nano Biosystems, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA
Homepage: https://apps.pharmacy.wisc.edu/sopdir/narsimha_mamidi/index.php
Research interests: nano-biomaterials; drug/gene delivery; cancer immunotherapy; tissue engineering

Name: Dr. Rahamatullah Shaikh
Affiliation: Centre for Pharmaceutical Engineering Science, School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, West Yorkshire, UK
Homepage: https://www.bradford.ac.uk/staff/rshaikh2/
Research interests: drug formulation development; drug delivery; continuous pharmaceutical manufacturing; particle engineering; industrial crystallization; pharmaceutical analysis

Name: Dr. Elena Maria Tosca
Affiliation: Dipartimento di Ingegneria Industriale e dell'Informazione, Università degli Studi di Pavia, Pavia, Italy
Homepage: http://lab-bioinfo.unipv.it/index.php/it/people
Research interests: PK/PD modeling; model-based translational oncology; application of ML/AI to pharmacometrics; model-based precision dosing Bayesian estimation

Name: Dr. Laura Di Muzio
Affiliation: Dipartimento di Chimica e Tecnologia del Farmaco, Sapienza Università di Roma, 00185 Rome, Italy
Homepage: https://research.uniroma1.it/researcher/93e6916c72dc28eff4549e69a8f8d1327da123a117c115d5a91c2fd2
Research interests: polymer-based biomaterial synthesis; polymer-based systems; hybrid lipid/polymer nanocomposites; 3D bioprinting

Name: Dr. Sobia Noreen
Affiliation: Clinical Trial Office, University of Illinois Cancer Center (UIC), Chicago, IL 60612, USA
Homepage 1: https://www.uic.edu/apps/departments-az/search?dispatch=roster&style=uic&orgid=99412
Homepage 2: https://orcid.org/0000-0002-4407-6002
Research interests: drug delivery & nanomedicine; polymeric materials; cancer therapy; biomaterials; mucoadhesion; thiolation; clinical trials; inflammatory diseases; clinical translation; regulatory affairs

Name: Dr. Zhengwei Huang
Affiliation: College of Pharmacy, Jinan University, Guangzhou 510632, China
Homepage: https://yx.jnu.edu.cn/2025/0304/c37237a831019/page.htm
Research interests: inhalable nanomedicines; drug delivery; ferroptosis; biological fate

Name: Dr. Gzona Bajraktari-Sylejmani
Affiliation: Internal Medicine IX—Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Medical Faculty Heidelberg, Medical Clinic Heidelberg, Heidelberg, Germany
Homepage: https://www.klinikum.uni-heidelberg.de/personen/dr-rer-nat-gzona-bajraktari-sylejmani-3457
Research interests: drug-drug interactions; drug transporters; platelets; PDE5 inhibitors; endothelial dysfunction; cellular pharmacokinetics; liquid chromatography tandem mass spectrometry

Name: Dr. Ravi Maharjan
Affiliation: Department of Pharmaceutical Technology, Dongguk University, Seoul 04620, Republic of Korea
Homepage: https://orcid.org/0000-0003-4862-1933
Research interests: mRNA vaccines; lyophilization; vaccine stability; continuous manufacturing

Name: Dr. Soraia Filipa Tavares Pinto
Affiliation: Institute for Research and Innovation in Health (i3S), University of Porto, 4200-180 Porto, Portugal
Homepage: https://www.i3s.up.pt/personal-info.php?id=2655&idg=109
Research interests: nanotechnology; drug delivery systems; oral delivery; diabetes mellitus; bladder cancer; intestinal target; FcRn-mediated transcytosis

Name: Dr. Marco Uboldi
Affiliation: 1. Pharmaceutical Technology & Regulatory Affairs “M.E. Sangalli” Unit, Department of Pharmaceutical Sciences, DISFARM Università degli Studi di Milano, Milan, Italy; 2. PhormulaMI Lab—Formulation and Technology Frontiers in Pharmaceutics, Milan, Italy
Homepage: https://orcid.org/0000-0003-0179-2233
Research interests: pharmaceutical technology; solid dosage forms; administration through the gastrointestinal tract; retentive drug delivery systems; hot melt extrusion; injection molding; 3D and 4D printing in pharmaceutics

Name: Dr. Marcelo Gomes Davanço
Affiliation: Medical and Clinical Affairs Department, Knight Therapeutics, São Paulo 04085-001, Brazil
Homepage: https://bv.fapesp.br/pt/pesquisador/77293/marcelo-gomes-davanco/
Research interests: bioequivalence; pharmacokinetics; bioavailability; drug product development; IVIVC; biopharmaceutics; PBBM; biowaiver

Name: Dr. Cristina Casadidio
Affiliation: School of Pharmacy, Drug Delivery Division, University of Camerino, CHIP Research Center, Via Madonna delle Carceri, 62032 Camerino, MC, Italy
Homepage: https://orcid.org/0000-0002-3925-7087
Research interests: biomaterials; polymer synthesis; hydrogels; nanoparticles; gene and drug delivery; therapeutics stability

Name: Dr. Wei Zhang
Affiliation: Department of General Surgery & Institute of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Shenzhen University General Hospital, Shenzhen University, Shenzhen, China
Homepage: https://orcid.org/0000-0003-3688-4381
Research interests: the development and application of anti-tumor natural products; drug resistance mechanisms in gastrointestinal tumors; innovative drug delivery systems

Name: Dr. Shuangqing Wang
Affiliation: Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Homepage: https://orcid.org/0000-0003-0270-1305
Research interests: drug delivery

Name: Dr. Yu’e Liu
Affiliation: Boston Children’s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Homepage: https://orcid.org/0009-0007-9516-5017
Research interests: cancer biomarkers; small molecule drug screening; tumor metabolism; cancer immunotherapy; pharmacological mechanisms of anti-cancer agents

Name: Dr. Silvia Pisani
Affiliation: Department of Drug Sciences, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Homepage: https://www.pharmatechlaw.it/our-team/
Research interests: tissue engineering; regenerative medicine; shape memory scaffolds;  drug delivery systems; nanobiotechnology

Name: Dr. Khaled Galal
Affiliation: Walker Department of Mechanical Engineering, The University of Texas at Austin, Austin, TX 78712, USA
Homepage: https://orcid.org/0000-0002-2554-5483
Research interests: biologic formulation; freeze-drying; pulmonary drug delivery; vaccine formulation and development; gene delivery; oral bioavailability enhancement; lipid nanoparticles; polyelectrolyte micelles; small-angle X-ray scattering

Name: Dr. Xing-Jie Dai
Affiliation: Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Henan 450052, China
Homepage: https://orcid.org/0000-0001-7531-044X
Research interests: epigenetic-targeted anticancer drug discovery, including inhibitors, degraders, and dual-target agents

Name: Dr. Xiong Guo
Affiliation: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
Homepage: https://ogrs.syphu.edu.cn/info/1313/12178.htm
Research interests: development of functional biomaterials and their applications in tissue engineering and drug delivery

Name: Dr. Giulia Anderluzzi
Affiliation: Department of Pharmaceutical Sciences, University of Milan, Milan, Italy
Homepage: https://ddrug.unimi.it/profilo/giulia-anderluzzi-phd/
Research interests: formulation; nanotechnology; gene delivery; targeted drug delivery

Name: Dr. Amelia Ultimo
Affiliation: Príncipe Felipe Research Center Foundation (CIPF), Valencia, Spain
Homepage: https://www.nanofacts.net/amelia-ultimo/
Research interests: drug delivery systems; mesoporous silica nanoparticles; extracellular vesicles; nanoparticles; nanomedicine; cancer therapy

Name: Dr. Adrián Matencio Durán
Affiliation: Departamento de Bioquímica y Biología Molecular-A, Facultad de Biología, Universidad de Murcia–Regional Campus of International Excellence “Campus Mare Nostrum”, E-30100 Murcia, Spain
Homepage: https://portalinvestigacion.um.es/investigadores/377993/detalle 
Research interests: food biotechnology; molecular encapsulation; cyclodextrin; cyclodextrin-based materials; polymers; bioactive compounds; drug delivery; enzymology; molecular docking

Name: Dr. Ilaria Andreana
Affiliation: Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy
Homepage: https://www.dstf.unito.it/do/docenti.pl/Alias?ilaria.andreana#tab-profilo
Research interests: drug delivery systems; biocompatible nanocarriers; active targeting; liposomes; polymer nanoparticles

Name: Dr. Héctor Iván Meléndez Ortiz
Affiliation: Secretaría de Ciencia, Humanidades, Tecnología e Innovación-Centro de Investigación en Química Aplicada, Blvd. Enrique Reyna Hermosillo 140, Saltillo 25294, Coahuila, Mexico
Homepage: https://www.ciqa.mx/HectorMelendez.aspx
Research interests: nanodevices; nanoparticles; hydrogels; drug delivery; anticancer agents delivery; antibiotic delivery

Name: Dr. Andrea Patrizia Falanga
Email: andreapatrizia.falanga@unina.it
Affiliation: Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy
Homepage: https://www.docenti.unina.it/#!/professor/414e445245412050415452495a494146414c414e4741464c4e4e52503837413534463230354f/riferimenti
Research interests: peptide nucleic acid; G-quadruplex; delivery; solid-phase synthesis; small molecule-DNA interactions

Name: Dr. Mershen Govender
Affiliation: Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa
Homepage: https://www.wits.ac.za/people/academic-a-z-listing/g/mershengovenderwitsacza/
Research interests: controlled release systems; mucosal delivery; transdermal delivery; microneedles; nanotechnology; pharmaceutical microbiology; infectious diseases; oncology; tissue engineering; regenerative medicine; biomaterials; 3D bioprinting

Name: Dr. Xin Jin
Affiliation: Department of Pharmaceutics, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian 223800, China
Homepage: http://202.195.181.96/gmis5/dsfc/dsfcgrxx/CBB67AE4D295088D1A1B56627A3207D9
Research interests: nanomedicine; cancer treatment; cancer immunotherapy; cuproptosis; targeted therapy; drug delivery; nanotechnology; wound healing; diabetic ulcer treatment

Name: Dr. Dong Mei
Affiliation: Clinical Research Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
Homepage: https://yjsh.ccmu.edu.cn/dsdw/dsjj/ssyjsds/sdykdxfsbjetyy1/ylx21/2025_1945100758438723585_1.htm
Research interests: pediatric clinical pharmacology; novel drug formulations; oral absorption mechanisms; clinical translation of new drug delivery systems

Name: Dr. Sangeun Lee
Affiliation: Helmholtz Institute of Pharmaceutical Research Saarland (HIPS)—Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123 Saarbrücken, Germany
Homepage: https://www.uni-saarland.de/en/chair/lee.html
Research interests: stimuli-responsive polymers; polymeric nanoparticles; dynamers; single-chain nanoparticles

Name: Dr. Jiuhong Zhao
Affiliation: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
Homepage:  https://www.aminer.cn/profile/jiuhong-zhao/6505c9c7ea10f8257b38d862?source=www.chemnav.net    
Research interests: nanozymes; DNAzyme; microneedles; biosensing; MOF

Name: Dr. Rute Nunes
Affiliation: 1. IUCS—Instituto Universitário de Ciências da Saúde, CESPU, Avenida Central de Gandra, 1317, 4585-116 Gandra, Portugal
2. UNIPRO—Unidade de Investigação em Patologia e Reabilitação Oral, Instituto Universitário de Ciências da Saúde (IUCS-CESPU), 4585-116 Gandra, Portugal
3. i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
Homepage: https://www.i3s.up.pt/personal-info.php?id=599&idg=109
Research interests: drug delivery; inflammatory bowel disease; mucosal drug delivery; mucus penetrating nanoparticles; nanomedicine; smart nanosystems

Name: Dr. Mauricio A. García
Affiliation: Departamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile
Homepage: https://quimica.uc.cl/investigacion/academicos/mauricio-garcia-a/
Research interests: biopharmaceutics; drug absorption; modeling; oral dosage forms; pulmonary dosage forms; physical pharmacy

Name: Dr. Lan Wu 
Affiliation: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
Homepage: https://wuya.syphu.edu.cn/info/1022/1788.htm
Research interests: pulmonary administered particulate systems; biomacromolecules (nucleic acids, proteins, and peptides); nano-vaccines

Name: Dr. Tianyao Wang
Affiliation: Department of Nuclear Medicine, Peking University First Hospital, Beijing, China
Homepage: https://orcid.org/0000-0002-9349-8930
Research interests: radiopharmaceuticals; molecular imaging; PET imaging; nanomedicine; targeted therapy; cancer diagnosis; translational medicine

Name: Dr. Lisha Liu
Affiliation: Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China
Homepage: https://yxy.cpu.edu.cn/a8/b0/c11945a174256/page.htm
Research interests: drug delivery; cancer immunotherapy; cardiovascular disease; pharmaceutical science

Name: Dr. Elide Zingale
Affiliation: Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy
Homepage: https://orcid.org/0000-0002-0035-9457
Research interests: ocular drug delivery; lipid nanoparticles; self-nanoemulsifying drug delivery systems; natural compounds, microfluidics

Name: Dr. Shiping Lu
Affiliation: Institute of Translational Medicine, China Pharmaceutical University, Nanjing, China
Homepage: https://orcid.org/0009-0009-0382-5669
Research interests: vaccine delivery; adjuvant; mucosal immunity

Name: Dr. Emma Dosmar
Affiliation: Rose Hulman Institute of Technology, Terre Haute, IN 47803, USA
Homepage: https://www.rose-hulman.edu/academics/faculty/dosmar-emily-dosmare.html
Research interests: biomaterials; drug delivery; ocular drug delivery

13 August 2025
Meet Us at the 34th Annual Conference of the European Society for Biomaterials, 7–11 September 2025, Turin, Italy


MDPI is excited to announce its participation as an exhibitor at the 34th Annual Conference of the European Society for Biomaterials, taking place in Turin, Italy, from 7 to 11 September 2025.

The motto of the ESB 2025 conference is “Biomaterials on the horizon”. The horizon opens our mind to new and at times unexpected discoveries and reminds us of the charming challenges of our research. The motto is inspired by the fast development of new sources for multifunctional materials, and groundbreaking technologies that enable new structures and devices that improve healthcare, prevent pathologies, and allow patient-oriented therapies.

With all this in mind, in an exciting and dynamic environment, participants to ESB 2025 will share and discuss traditional areas of research, such as clinical translation, regenerative medicine, in vitro models, drug delivery, and antibacterial treatments, but also emerging themes, such as biomaterial-assisted gene and cell therapy, investigations at the (bio)molecular and cell scale, as well as crosscutting topics, such as artificial intelligence in biomaterial research, ethics, the 3Rs principle, and regulatory frameworks. Particular attention will be given to the Sustainable Development Goals, in which the role of the biomaterials is increasingly relevant.

The following MDPI journals will be presented at the conference:

If you are attending this conference, please feel free to get in contact with us. Our delegates look forward to meeting you in person at booth #21 and answering any questions that you may have. For more information about the conference, please visit the following link: https://esb2025.org/.

5 August 2025
Meet Us at the 11th German Pharm-Tox Summit, 17–20 March 2026, Dusseldorf, Germany


We would like to invite you to attend the 11th German Pharm-Tox Summit / 92. Jahrestagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT 2026), which will take place from 17 to 20 March 2026 in Dusseldorf, Germany. 

Conference Chairs:

  • Univ. Prof. Dr. med. Maria Grandoch MSc, Director Institute of Translational Pharmacology
    University Hospital of Heinrich Heine University, Germany;
  • Prof. Dr. Jens W. Fischer, Director Institute of Pharmacology University Hospital of Heinrich Heine University, Germany;
  • Prof. Dr. rer. nat. Gerhard Fritz, Director Institute for Toxicology University Hospital of Heinrich Heine University, Germany. 

Topics of interest:

  • Pharmacology, clinical pharmacology, and toxicology;
  • General medical research food and product safety pharmacy;
  • Pharmaceutical/bio/medical chemistry biotechnology environmental medicine. 

Important dates:

  • Deadline for abstract submission: 1 October 2025;
  • Start Registration: 1 August 2025. 

Guide for authors:
To submit your abstract, please click on the following link: https://gpts-kongress.de/program-abstracts/abstract-submission. 

To register for the event, please click on the following link: https://gpts-kongress.de/registration. 

For more information, please click on the following link: https://gpts-kongress.de/registration. 

Conference organization:
Conventus Congressmanagement & Marketing GmbH
Carl-Pulfrich-Str. 1
07745 Jena
Telephone: +49 3641 3116-0
E-Mail: post@conventus.de
Homepage: https://conventus.de

31 July 2025
MDPI INSIGHTS: The CEO's Letter #25 - 8,000 Staff Worldwide, Korea Visit, 100,000 Preprints, Malaysia Roundtable, Canada Consortium Deal

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Talent Drives Our Progress

For the first time in MDPI’s history, we now have over 8,000 colleagues across the company. I would like to take a moment to celebrate this milestone and acknowledge the driving force behind our growth and success: our people.

As the world’s leading fully open access publisher, MDPI has grown thanks to the dedication, talent, and teamwork of colleagues across the company. Already halfway through 2025, we’ve welcomed nearly 2,000 new colleagues. 

“Our achievements are also about the people behind them”

We now manage over 475 journals, with 298 receiving an Impact Factor, and hundreds more indexed in major databases, including 343 in Scopus, and 92 by PubMed. As the reach and impact of our journals continues to grow, so does the need for dedicated and qualified teams to support that growth. Thus, attracting and retaining exceptional talent remains a cornerstone of our success.

Our achievements are not just about the results of journal expansion, however: they’re about the people behind them. From our hardworking editors to our meticulous English editing and production teams – from our journal relationship specialists, public relations, marketing and communications professionals to our conference teams and the project teams behind Preprints, Scilit, SciProfiles, JAMS and more. Our success reflects the work of thousands of people showing up each day, taking pride in their work, and committed to excellence and service.

What we’re doing to support talent:

  • Investing in onboarding and training to help new colleagues feel welcomed and empowered to thrive.
  • Creating clearer career paths across all functions, from editorial to communications and beyond.
  • Launching mentorship programs and internal knowledge-sharing sessions to promote growth and collaboration.
  • Evolving our recognition and rewards programs to better celebrate your contributions.
  • Expanding our training systems and platforms.

MDPI’s in-house training department offers over 215 training courses, covering topics from editorial development to cross-cultural collaboration. In 2024 alone, we had 44 full-time trainers and 196 part-time training assistants supporting the learning and development needs of colleagues worldwide. These efforts ensure our teams are equipped with the skills and confidence to grow professionally and contribute meaningfully.

Over two-thirds of our workforce is editorial, and of our more than 5,400 editors, 87% hold a Master’s degree and 6% a PhD. Their collective contributions are central to delivering a high-quality publishing experience and supporting global academic communication.

As we celebrate this milestone, we also aim to continue on a path of steady and sustainable growth, one that balances journal expansion with investment in people, outreach, processes, and innovation. Together, we are shaping the future of open access and academic publishing. Thank you for your hard work, your ideas, and your commitment to serving the global research community.

Let’s continue working together to create a culture where great talent grows and every colleague feels valued.

Impactful Research

Visiting South Korea: Building Connections and Supporting the MDPI Seoul Office

In July, I had the opportunity to visit our team in Seoul and engage directly with academic communities in South Korea. The visit focused on deepening MDPI’s relationships with local universities, institutions, and partners, and supporting the great work of our colleagues at the MDPI Seoul office.

Korea Association of Private University Libraries (KAPUL) Conference

A highlight of the visit was our participation in the Korea Association of Private University Libraries (KAPUL) Conference, where we presented to over 100 academic librarians. I delivered a keynote speech titled “The Evolving Publishing Landscape: Open Access and Beyond,” while my colleague Dr. Jisuk Kang (Public Affairs Specialist) shared insights in her presentation, “Inside MDPI: Editorial Practices & Research Integrity.”

Facts & Figures: South Korea

  • South Korea is MDPI’s sixth-largest publishing country by article volume (over 90,000 MDPI papers published to date).
  • In 2024, Korea ranked 16th globally by total publications, and 6th (among these top 20 countries) by citation impact.
  • 52% of Korean publications in 2024 were OA – and 73% of those were Gold OA.
  • MDPI published about 20% of all OA papers from Korea in 2024.
  • Over 2,000 active Editorial Board Members from South Korea contribute to MDPI journals, with 11 Section Editors-in-Chief.
  • We currently have 11 Institutional Open Access Program agreements and two society partnerships in Korea:
    • Korean Society of Pharmaceutical Sciences and Technology (with MDPI journal Pharmaceutics)
    • Korean Tribology Society (with MDPI journal Coatings)

MDPI Seoul Office and the First Korea Salon

Our Seoul office serves as a regional hub for marketing, communications, and community engagement. It continues to grow in size and influence, prioritizing supporting scholar visits, conference sponsorships, and outreach events such as the recent MDPI Korea Salon.

The inaugural Salon, themed “Exploring Research Trends in Medical Publishing, Ethics, and AI,” brought together over 20 scholars and Editorial Board members serving MDPI journals.

Thank you to our guest speakers including Professors Young-Joon Surh of Seoul National University, Kwang-Sig Lee of Korea University, and Jin-Won Noh of Yonsei University who presented on the landscape of medicine in South Korea and across the globe. The Salon also included presentations from MDPI colleagues on Open Access, ethics, and how the IOAP can support researchers in this field.

“Our Seoul office continues to grow in size and influence”

Looking Ahead

MDPI is already the leading OA publisher in South Korea, yet challenges and misconceptions around OA and APCs remain. Visits like this one, along with the ongoing efforts of our Seoul office, are important to building understanding, trust, and long-term relationships with the local academic community.

A big thank-you to our colleagues in Seoul for their warm hospitality, professionalism, and energy! Our new office is well situated, staffed, and ready to grow. This visit marked an important step forward in our continued mission to support global research communities and advance Open Science.

Inside MDPI

Preprints.org Reaches 100,000 Preprints: A Major Milestone for MDPI and Open Science

In case you missed it, Preprints.org recently surpassed 100,000 preprints posted. This is a major milestone for our platform and one worth celebrating.

Preprints are a key pillar of the Open Science movement, which promotes transparency, equity, and faster knowledge-sharing through initiatives such as Open Access, Open Data, Open Source, and Open Peer Review. The benefits of Open Science extend beyond researchers, as they support funders, educators, policymakers, and the public in advancing discovery and innovation.

What is behind the 100,000 preprints milestone?

Since its launch in 2016, Preprints.org has grown into one of the world’s leading preprint platforms, now ranked fifth globally by publication volume.

More than 350,000 researchers have contributed, helping shape this dynamic and collaborative space for sharing early-stage research across all disciplines.

Read the full announcement here:
https://www.mdpi.com/about/announcements/12202

“Preprints.org has grown into one of the world’s leading preprint platforms”

Some quick facts worth noting:

  • About 56% of the preprints on Preprints.org are later published in peer-reviewed journals.
  • The platform is now indexed in Web of Science (Preprint Citation Index), Europe PMC, and Crossref, helping improve visibility and trust in the preprints shared.
  • Recent upgrades – including a revamped website, new features such as search subscriptions, curated reading lists, and community feedback tools (PREreview) – show our commitment to developing Preprints.org in line with researchers’ needs.

This growth and progress would not be possible without the dedication of the Preprints.org team, our Advisory Board members, screeners, and colleagues across MDPI who support the platform’s development. This milestone is a reminder of our shared mission: to accelerate scientific communication and build a more open, transparent, and inclusive research ecosystem.

I’m excited to see what’s ahead as we approach Preprints.org’s 10-year anniversary in 2026!

Coming Together for Science

Malaysia Media Roundtable: Educating on Open Access and MDPI’s Presence in Southeast Asia

At the end of June, I had the opportunity to participate in a strategic media roundtable in Kuala Lumpur, focused on raising awareness about the importance of Open Access (OA) and on MDPI’s growing presence in Southeast Asia.

We welcomed five Malaysian media outlets for an engaging private session that included presentations and open discussion.

I gave an overview of the benefits of Open Access, MDPI’s global developments, and our collaborations in Malaysia.

My colleague Yu Nwe Soe (Public Relations Specialist), presented on our editorial process, helping to clarify how MDPI supports authors and maintains research quality.

We were also joined by two local Editorial Board Members (EBMs) who offered first-hand insights into their experiences working with MDPI and how OA has shaped their publishing choices.

The discussion covered a range of questions from the press, from OA publishing models to editorial standards, and highlighted MDPI’s unique contribution to accelerating scientific communication in the region.

As the leading fully OA publisher, we see it as our responsibility to continue educating research communities and the broader public on the impact of OA, especially in emerging and high-growth academic markets.

Spotlight on Malaysia

Malaysia continues to rise as a regional research hub, with five universities ranked in the global top 200 and 11 subjects in the global top 50. In 2024, Malaysia ranked 2nd in Southeast Asia in total publication output, 10th in Asia, and 25th globally.

MDPI’s presence in Malaysia:

  • Over 21,000 research articles published to date from Malaysian institutions
  • More than 1,100 articles published in 2024 alone
  • In the period 2020–2024, 54% of Malaysia’s total publications were OA
  • 36 EBMs from Malaysia, across 27 MDPI journals
  • Around 100 conferences sponsored in Malaysia in the past five years
  • MDPI is hosting the 2nd International Conference on AI Sensors and Transducers in Kuala Lumpur (29 July- 3 August 2025)

Media Coverage & Editorial Voices

Following the roundtable, we saw positive coverage across several local outlets, with articles highlighting MDPI’s role in empowering Malaysian researchers. Notable pieces included:

Our local EBMs also shared their perspectives:

Prof. Denny Ng Kok Sum (Sunway University, EBM of MDPI journal Processes) and Prof. Lee (EBM of MDPI journal Bacteria) share their experiences with MDPI and the role Open Access plays in their publication decisions.

“We see it as our responsibility to continue educating research communities on the impact of OA”

“I didn’t want my work stuck behind a paywall.”
— Prof. Denny Ng Kok Sum, Sunway University, Processes Editorial Board Member

“Open Access opens doors for collaboration and visibility, especially in fast-developing regions like ours.”
— Prof. Lee, Bacteria Editorial Board Member

This roundtable marked another step in building trust, understanding, and collaboration in Southeast Asia. A big thank-you to the MDPI Malaysia team and all those who contributed to the event’s success.

Closing Thoughts

MDPI Signs First North American Agreement with Canadian Consortium

We are proud to announce a major milestone for MDPI Canada and an important step forward for OA in North America.

In July, our Toronto office finalized MDPI’s first North American consortium agreement with the Federal Science Libraries Network (FSLN). This is a significant achievement that strengthens our expansion in Canada and reinforces our global commitment to supporting Open Science.

This two-year agreement gives Canadian federal agencies access to MDPI’s IOAP, including discounted article processing charges for affiliated researchers across our portfolio of over 475 OA journals. It lowers barriers for Canadian scientists to share their work more openly and reach a global audience.


Ryan Siu, Institutional Partnerships Manager at MDPI.

“The Open Science landscape in Canada is rapidly evolving, with the Tri-Agency Open Access Policy set for renewal by the end of 2025. This reflects ongoing efforts to foster greater scientific transparency and accessibility at a national policy level,” says Ryan Siu, Institutional Partnerships Manager at MDPI.

“Our new agreement with FSLN represents our shared commitment to further these efforts and foster wider readership. By aligning with these initiatives, we make progress towards research that’s both inclusive and impactful, benefiting local and global communities alike.”

Participating FSLN institutions include:

  • Agriculture and Agri-Food Canada
  • Environment and Climate Change Canada
  • Health Canada
  • National Research Council Canada
  • Natural Resources Canada

By partnering with some of Canada’s largest science-based agencies, we reaffirm our goal of advancing OA across continents. We look forward to developing our support for Canadian researchers and continuing to drive progress in Open Science across North America and beyond.

Stefan Tochev
Chief Executive Officer
MDPI AG

30 July 2025
Meet Us at the 16th PharmSci International Conference, 9–11 September 2025, Cardiff, UK


MDPI will be exhibiting at the 16th PharmSci International Conference (PharmSci 2025), which will be held from 9 to 11 September 2025 at the Principality Stadium, Cardiff, UK. The conference is organized by the Academy of Pharmaceutical Sciences.

This exciting event will bring together leading experts, researchers, and professionals in the Pharmaceutical Science field to share their knowledge, present their latest discoveries, and provide valuable networking opportunities.

The following MDPI journals will be represented:

If you are planning to attend the conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit the following website: https://apsgb.co.uk/pharmsci-2025/.


Displaying Announcement 1-10 on page 1 of 30.
Go to page       1 2 3 4 5 chevron_right last_page
Back to TopTop